Bill Text: GA SB370 | 2011-2012 | Regular Session | Introduced
Bill Title: Controlled Substances; Schedule I and V controlled substance; "dangerous drug"; provisions
Spectrum: Slight Partisan Bill (Republican 3-1)
Status: (Passed) 2012-03-27 - Act 434 [SB370 Detail]
Download: Georgia-2011-SB370-Introduced.html
12 SP370/AP
Senate
Bill 370
By:
Senators Carter of the 1st, Bethel of the 54th, Jackson of the 2nd and Goggans
of the 7th
AS
PASSED
A
BILL TO BE ENTITLED
AN ACT
AN ACT
To
amend Chapter 13 of Title 16 of the Official Code of Georgia Annotated, relating
to controlled substances, so as to change certain provisions relating to
Schedule I and V controlled substances; to provide for a short title; to
change certain provisions relating to the definition of "dangerous drug"; to
provide an effective date; to repeal conflicting laws; and for other
purposes.
BE
IT ENACTED BY THE GENERAL ASSEMBLY OF GEORGIA:
SECTION
1.
This
2012 Act which provides for the annual update of the identity of controlled
substances and dangerous drugs is dedicated to the memory of Chase Corbitt
Burnett and shall be known and may be cited as "Chase's Law."
SECTION
2.
Chapter
13 of Title 16 of the Official Code of Georgia Annotated, relating to controlled
substances, is amended in Code Section 16-13-25, relating to Schedule I
controlled substances, by adding a new subparagraph to paragraph (3) to read as
follows:
"(GGG)
Fluorophenylpiperazine
(FPP);"
SECTION
3.
Said
chapter is further amended in Code Section 16-13-25, relating to Schedule I
controlled substances, by revising paragraph (12) to read as
follows:
"(12)
Any
material, compound, mixture, or preparation which contains any quantity of the
following substances, their salts, isomers (whether optical, positional, or
geometric), homologues, and salts of isomers and homologues, unless specifically
excepted, whenever the existence of these salts, isomers, homologues, and salts
of isomers and homologues is possible within the specific chemical
designation:
(A)
1-pentyl-3-(1-naphthoyl)indole (JWH-018);
(B)
1,1-dimethylheptyl-11-hydroxy-delta-8-tetrahydrocannabinol (HU-210; (6a,
10a)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol);
(C)
2-(3-hydroxycyclohexyl)-5-(2-methyloctan-2-yl)phenol (CP 47,497);
(D)
1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200);
(E)
2-(2-Methoxyphenyl)-1-(1-pentylindole-3-yl) ethanone (JWH-250);
(F)
4-Methoxynaphthalen-1-yl-(1-pentylindole-3-yl) methanone (JWH-081).
Any
of the following compounds, derivatives, their salts, isomers, and salts of
isomers, unless specifically utilized as part of the manufacturing process by a
commercial industry of a substance or material not intended for human ingestion
or consumption, as a prescription administered under medical supervision, or
research at a recognized institution, whenever the existence of these salts,
isomers, and salts of isomers is possible within the specific chemical
designation:
(A)
Naphthoylindoles;
(B)
Naphthylmethylindoles;
(C)
Naphthoylpyrroles;
(D)
Naphthylideneindenes;
(E)
Phenylacetylindoles;
(F)
Cyclohexylphenols;
(G)
Benzoylindoles;
(H)
Tricyclic benzopyrans;
(I)
Adamantoylindoles;
(J)
Indazole amides;
(K)
2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin
-6-yl]-1-naphthalenylmethanone (WIN 55,212-2); or
(L)
Any compound, unless specifically excepted or listed in this or another
schedule, structurally derived from 2-aminopropan-1-one by substitution at the
1-position with either phenyl, naphthyl, or thiophene ring systems, whether or
not the compound is further modified in any of the following ways:
(i)
By substitution in the ring system to any extent with alkyl, alkylenedioxy,
alkoxy, haloalkyl, hydroxyl, or halide substitutions, whether or not further
substituted in the ring system;
(ii)
By substitution at the 3-position with an acyclic alkyl substitution;
or
(iii)
By substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or
methoxybenzyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic
structure."
SECTION
4.
Said
chapter is further amended in Code Section 16-13-29, relating to Schedule V
controlled substances, by deleting "or" at the end of paragraph (4), by
replacing the period at the end of paragraph (5) with "; or", and by adding a
new paragraph to read as follows:
"(6)
Ezogabine."
SECTION
5.
Said
chapter is further amended in Code Section 16-13-71, relating to the definition
of dangerous drug, by adding new paragraphs to subsection (b) to read as
follows:
"(14.5)
Adenovirus;"
"(17.3)
Aflibercept;"
"(17.7)
Albiraterone;"
"(72.43)
Azficel-T;
(72.45)
Azilsartan;"
"(78.3)
Belatacept;
(78.5)
Belimumab;"
"(104.5)
Boceprevir;"
"(106.5)
Brentuxima vedotin;"
"(154.5)
Centruroides [Scorpion]
Immune;"
"(198.05)
Clobazam;"
"(208.5)
Coccidioides immitis;"
"(217.8) Crizotinib;"
"(386.05) Fidaxomicin;"
"(408.27) Gadobutrol;"
"(464.07) Icatibant;"
"(469.07) Indacaterol;"
"(487.06) Ioflupane;"
"(490.7) Ipilimumab;"
"(520.5) Linagliptin;"
"(842.18) Rilpivirine;"
"(843.825) Rivaroxaban;"
"(844.75) Roflumilast;"
"(885.5) Spinosad;"
"(931.553) Telaprevir;"
"(964.7) Ticagrelor;"
"(1025.2) Vandetanib;"
"(1027.55) Vemuranfenib;"
"(1030.5) Vilazodone;"
SECTION
6.
This
Act shall become effective upon its approval by the Governor or upon its
becoming law without such approval.
SECTION
7.
All
laws and parts of laws in conflict with this Act are repealed.